{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T16:49:54Z","timestamp":1791910194781,"version":"4.3.4"},"reference-count":55,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T00:00:00Z","timestamp":1731456000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Clinical Key subject Construction of Shanghai","award":["shslczdzk06504"],"award-info":[{"award-number":["shslczdzk06504"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Immune checkpoint inhibitors (ICIs) significantly improve survival, while immune-mediated hepatotoxicity (IMH) has been reported. To evaluate the incidence and potential risk factors of IMH among cancer patients treated by ICIs, PubMed\/Medline, Web of Science, Cochrane, and Embase were searched before 30 March 2024 for systematic review and meta-analysis. Odds ratios (ORs) with 95% confidence intervals (CI) were calculated. Quality assessment was completed using the Newcastle\u2013Ottawa scale. Of 1217 articles identified, 24 consisting of 9076 patients were included, with one study being prospective and the rest retrospective. The overall incidence of any grade IMH and grade \u2265 3 secondary to ICIs was 14% and 7%, respectively. The cholestatic pattern was more prevalent than the hepatocellular and mixed patterns. The meta-analysis revealed that ICI treatment was related to reduced risk of IMH in older patients (SMD: \u22120.18; 95% CI: \u22120.33 to \u22120.04), individuals with higher body mass index (WMD: \u22122.15; 95% CI: \u22123.92 to \u22120.38), males (OR: 0.44; 95% CI: 0.27 to 0.72), and patients with lung cancer (OR: 0.58, 95%CI 0.41 to 0.83). On the other hand, patients with liver metastasis (OR: 1.80; 95% CI: 1.47 to 2.20), history of ICI treatment (OR: 3.09; 95% CI: 1.21 to 7.89), diabetes (OR: 2.19; 95% CI: 1.36 to 3.51), chronic HBV (OR: 3.06; 95% CI: 1.11 to 8.46), and concomitant use of ICIs (OR: 8.73; 95% CI: 2.41 to 31.59) increased the risk of developing IMH. This study will provide clinicians with information on potentially high-risk groups for IMH, who need to be cautiously monitored for liver function when receiving immunotherapy.<\/jats:p>","DOI":"10.3390\/curroncol31110525","type":"journal-article","created":{"date-parts":[[2024,11,13]],"date-time":"2024-11-13T11:28:12Z","timestamp":1731497292000},"page":"7129-7143","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Risk Factors of Immune-Mediated Hepatotoxicity Induced by Immune Checkpoint Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis"],"prefix":"10.3390","volume":"31","author":[{"given":"Ying","family":"Jiang","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Zhongshan Hospital Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ranyi","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhongshan Hospital Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Zhongshan Hospital Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningping","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Zhongshan Hospital Fudan University, Shanghai 200032, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,13]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/CJI.0000000000000347","article-title":"Analysis of Risk Factors for Hepatotoxicity Induced by Immune Checkpoint Inhibitors","volume":"44","author":"Cho","year":"2021","journal-title":"J. Immunother."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S1470-2045(16)30631-3","article-title":"Tumour-infiltrating lymphocytes in advanced HER2-positive breast cancer treated with pertuzumab or placebo in addition to trastuzumab and docetaxel: A retrospective analysis of the CLEOPATRA study","volume":"18","author":"Luen","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Nie, C., Xu, W., Guo, Y., Gao, X., Lv, H., Chen, B., Wang, J., Liu, Y., Zhao, J., and Wang, S. (2023). Immune checkpoint inhibitors enhanced the antitumor efficacy of disitamab vedotin for patients with HER2-positive or HER2-low advanced or metastatic gastric cancer: A multicenter real-world study. BMC Cancer, 23.","DOI":"10.1186\/s12885-023-11735-z"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Zheng, J., Huang, B., Xiao, L., Wu, M., and Li, J. (2022). Treatment- and immune-related adverse events of immune checkpoint inhibitors in esophageal or gastroesophageal junction cancer: A network meta-analysis of randomized controlled trials. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.821626"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1080\/14712598.2020.1762562","article-title":"Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: From clinical pivotal studies to real-life experience","volume":"20","author":"Vitale","year":"2020","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Tang, Q., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., Wu, W., Han, L., and Wang, S. (2022). The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.964442"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"ITC17","DOI":"10.7326\/AITC202402200","article-title":"Immune-Related Adverse Events of Immune Checkpoint Inhibitors","volume":"177","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e0063","DOI":"10.1097\/HC9.0000000000000063","article-title":"Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known","volume":"7","author":"Zheng","year":"2023","journal-title":"Hepatol. Commun."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Personeni, N., Pressiani, T., D\u2019Alessio, A., Prete, M.G., Bozzarelli, S., Terracciano, L., Dal Buono, A., Capogreco, A., Aghemo, A., and Lleo, A. (2021). Hepatotoxicity in Patients with Hepatocellular Carcinoma on Treatment with Immune Checkpoint Inhibitors. Cancers, 13.","DOI":"10.3390\/cancers13225665"},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"European Association for the Study of the Liver (2019). EASL Clinical Practice Guidelines: Drug-induced liver injury. J. Hepatol., 70, 1222\u20131261.","DOI":"10.1016\/j.jhep.2019.02.014"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S1470-2045(22)00326-6","article-title":"Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): A multicentre, open-label, randomised, phase 3 trial","volume":"23","author":"Kelley","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s00292-018-0519-6","article-title":"Liver injury induced by immune checkpoint inhibitor-therapy: Example of an immune-mediated drug side effect","volume":"39","author":"Straub","year":"2018","journal-title":"Pathologe"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1111\/liv.13746","article-title":"Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents","volume":"38","author":"Suzman","year":"2018","journal-title":"Liver Int."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal Toxic Effects Associated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jhep.2023.10.040","article-title":"Characteristics and outcomes of immunotherapy-related liver injury in patients with hepatocellular carcinoma versus other advanced solid tumours","volume":"80","author":"Celsa","year":"2024","journal-title":"J. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/JHC.S431191","article-title":"Liver Injury and Its Impact on Prognosis in Patients with HBV-Related Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors","volume":"11","author":"Shen","year":"2024","journal-title":"J. Hepatocell Carcinoma"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e1918","DOI":"10.1002\/cnr2.1918","article-title":"A multicenter retrospective analysis: Factors influencing hepatic adverse events induced by immunotherapy in advanced liver cancer","volume":"7","author":"Zou","year":"2024","journal-title":"Cancer Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"100851","DOI":"10.1016\/j.jhepr.2023.100851","article-title":"Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study","volume":"5","author":"Atallah","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_19","first-page":"76","article-title":"Occurrence and influencing factors of PD-1\/PD-L1 inhibitor-related liver injury in patients with extrahepatic primary carcinoma","volume":"25","author":"Jiang","year":"2023","journal-title":"Advers. Drug React. J."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1007\/s00432-022-04340-3","article-title":"Immune checkpoint inhibitor-induced hepatitis injury: Risk factors, outcomes, and impact on survival","volume":"149","author":"Miah","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"100880","DOI":"10.1016\/j.jhepr.2023.100880","article-title":"Burden of grade 3 or 4 liver injury associated with immune checkpoint inhibitors","volume":"5","author":"Parlati","year":"2023","journal-title":"JHEP Rep."},{"key":"ref_22","first-page":"1387","article-title":"Development and Validation of a Clinical Risk Score to Predict Immune-mediated Liver Injury Caused by Sintilimab: Assessed for Causality Using Updated RUCAM","volume":"11","author":"Zheng","year":"2023","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1007\/s00262-021-03082-4","article-title":"Hepatotoxicity associated with PD-1 blockade antibodies in cancer patients co-infected with hepatitis B virus","volume":"71","author":"Lin","year":"2022","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s00432-021-03870-6","article-title":"Presence of autoantibodies in serum does not impact the occurrence of immune checkpoint inhibitor-induced hepatitis in a prospective cohort of cancer patients","volume":"148","author":"Purde","year":"2022","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jcag\/gwab019","article-title":"Clinical Course and Treatment Implications of Combination Immune Checkpoint Inhibitor-Mediated Hepatitis: A Multicentre Cohort","volume":"5","author":"Smith","year":"2022","journal-title":"J. Can. Assoc. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Swanson, L.A., Kassab, I., Tsung, I., Schneider, B.J., and Fontana, R.J. (2022). Liver injury during durvalumab-based immunotherapy is associated with poorer patient survival: A retrospective analysis. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.984940"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1080\/07357907.2021.1994586","article-title":"Immune-related Liver Injury is a Poor Prognostic Factor in Patients with Nonsmall Cell Lung Cancer Treated with Immune Checkpoint Inhibitors","volume":"40","author":"Yamamoto","year":"2022","journal-title":"Cancer Investig."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s12072-021-10151-4","article-title":"Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients","volume":"15","author":"Biewenga","year":"2021","journal-title":"Hepatol. Int."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Cunningham, M., Iafolla, M., Kanjanapan, Y., Cerocchi, O., Butler, M., Siu, L.L., Bedard, P.L., Ross, K., Hansen, B., and Spreafico, A. (2021). Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0253070"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.1007\/s00432-020-03448-8","article-title":"Clinical features of immune-mediated hepatotoxicity induced by immune checkpoint inhibitors in patients with cancers","volume":"147","author":"Yamamoto","year":"2021","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1111\/jgh.15041","article-title":"Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan","volume":"35","author":"Kitagataya","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_32","first-page":"50","article-title":"Retrospectively analysis of characteristics and risk factors of immune treatment-related hepatic adverse events in malignant tumor","volume":"42","author":"Li","year":"2020","journal-title":"Zhonghua Zhong Liu Za Zhi"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/COC.0000000000000374","article-title":"Hepatotoxicity After Immune Checkpoint Inhibitor Therapy in Melanoma: Natural Progression and Management","volume":"41","author":"Huffman","year":"2018","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1007\/s00535-020-01677-9","article-title":"Real world data of liver injury induced by immune checkpoint inhibitors in Japanese patients with advanced malignancies","volume":"55","author":"Mizuno","year":"2020","journal-title":"J. Gastroenterol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ejca.2020.02.041","article-title":"Characterization of risk factors and efficacy of medical management of immune-related hepatotoxicity in real-world patients with metastatic melanoma treated with immune checkpoint inhibitors","volume":"130","author":"Romanski","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1111\/jgh.14889","article-title":"Non-alcoholic fatty liver disease is a potential risk factor for liver injury caused by immune checkpoint inhibitor","volume":"35","author":"Sawada","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1111\/apt.15413","article-title":"Liver injury is most commonly due to hepatic metastases rather than drug hepatotoxicity during pembrolizumab immunotherapy","volume":"50","author":"Tsung","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"251","DOI":"10.14309\/ajg.0000000000000398","article-title":"Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors","volume":"115","author":"Miller","year":"2020","journal-title":"Am. J. Gastroenterol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Endo, Y., Winarski, K.L., Sajib, M.S., Ju, A., and Wu, W.J. (2023). Atezolizumab Induces Necroptosis and Contributes to Hepatotoxicity of Human Hepatocytes. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms241411694"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41419-024-06535-7","article-title":"Innate and adaptive immune cell interaction drives inflammasome activation and hepatocyte apoptosis in murine liver injury from immune checkpoint inhibitors","volume":"15","author":"Shojaie","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Affolter, T., Llewellyn, H.P., Bartlett, D.W., Zong, Q., Xia, S., Torti, V., and Ji, C. (2019). Inhibition of immune checkpoints PD-1, CTLA-4, and IDO1 coordinately induces immune-mediated liver injury in mice. PLoS ONE., 14.","DOI":"10.1371\/journal.pone.0217276"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1080\/14740338.2022.2134854","article-title":"Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"21","author":"Pan","year":"2022","journal-title":"Expert Opin. Drug Saf."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/S2468-1253(20)30006-6","article-title":"Drug-induced liver injury in older people","volume":"5","author":"Lucena","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1053\/j.gastro.2015.03.006","article-title":"Features and Outcomes of 899 Patients with Drug-Induced Liver Injury: The DILIN Prospective Study","volume":"148","author":"Chalasani","year":"2015","journal-title":"Gastroenterology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1080\/17474124.2018.1427581","article-title":"Clinical characteristics and outcomes of traditional Chinese medicine-induced liver injury: A systematic review","volume":"12","author":"Wang","year":"2018","journal-title":"Expert Rev. Gastroenterol. Hepatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/liv.14896","article-title":"Incidence and risk factors of anti-tuberculosis drug induced liver injury (DILI): Large cohort study involving 4652 Chinese adult tuberculosis patients","volume":"41","author":"Jiang","year":"2021","journal-title":"Liver Int."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","article-title":"The twilight of immunity: Emerging concepts in aging of the immune system","volume":"19","year":"2018","journal-title":"Nat. Immunol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1007\/s00535-014-0973-8","article-title":"Clinical characteristics, treatment, and prognosis of non-B, non-C hepatocellular carcinoma: A large retrospective multicenter cohort study","volume":"50","author":"Tateishi","year":"2015","journal-title":"J. Gastroenterol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1097\/MEG.0000000000002689","article-title":"Association of BMI with mortality in drug-induced liver injury","volume":"36","author":"Ma","year":"2024","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3233\/CBM-150544","article-title":"High BMI and low HDL-C predict the chemotherapy-related hepatic dysfunction in Chinese advanced NSCLC patients","volume":"16","author":"Lv","year":"2016","journal-title":"Cancer Biomark."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Freire, D., Fielding, L., and Moore, A.J. (2023). Does diabetes mellitus comorbidity increase the risk of drug-induced liver injury during tuberculosis treatment?. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0286306"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"642","DOI":"10.21037\/atm-20-5144","article-title":"Prevalence and clinical characteristics of antibiotics associated drug induced liver injury","volume":"9","author":"Park","year":"2021","journal-title":"Ann. Transl. Med."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4103\/ijd.IJD_217_19","article-title":"Clinical Features, Risk Factors, and Prognostic Markers of Drug-Induced Liver Injury in Patients with Stevens-Johnson Syndrome\/Toxic Epidermal Necrolysis","volume":"65","author":"Zhang","year":"2020","journal-title":"Indian J. Dermatol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"10797","DOI":"10.1021\/acs.analchem.2c01571","article-title":"Ratiometric Detection of H(2)S in Liver Injury by Activated Two-Wavelength Photoacoustic Imaging","volume":"94","author":"Wu","year":"2022","journal-title":"Anal. Chem."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2870","DOI":"10.1111\/bcp.16184","article-title":"Clinical characteristics and prognosis of liver injury induced by immune checkpoint inhibitors in patients with malignancies: A real-world retrospective study","volume":"90","author":"Jiang","year":"2024","journal-title":"Br. J. Clin. Pharmacol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/11\/525\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:31:47Z","timestamp":1760113907000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/31\/11\/525"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,13]]},"references-count":55,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["curroncol31110525"],"URL":"https:\/\/doi.org\/10.3390\/curroncol31110525","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,13]]}}}